Publication
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerMalignant Colorectal Neoplasmcivic_curation1.00
- drugCrizotinibcivic_curation1.00
- drugPanitumumabcivic_curation1.00
- drugVemurafenibcivic_curation1.00
- geneBRAFcivic_curation1.00
- geneMETcivic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantMET Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27325282
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V600E1 | ||||||||
| Panitumumab + VemurafenibCombination | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1589Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subse… (full text at CIViC) PMID 27325282 · Pietrantonio et al., 2016 · Open in CIViC | civic |
| MET Amplification1 | ||||||||
| Crizotinib + VemurafenibCombination | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID1588Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months. Re-biopsy… (full text at CIViC) PMID 27325282 · Pietrantonio et al., 2016 · Open in CIViC | civic |